Clinical Trial

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Study acronym: OVATION 2
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
Protocol Amendment History 2 changes
minor Completion pushed: 2026-04-30 -> 2026-05-30 2026-05-05
minor Completion pushed: 2026-03-30 -> 2026-04-30 2026-04-14
Trial Details
NCT Number NCT03393884
Lead Sponsor Imunon
Conditions Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment 130 participants
Start Date 2018-09-05
Primary Completion 2024-07-25 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-04